From: @astrazeneca.com> Sent: 14 August 2020 03:03 To: GALLINA Sandra (SANTE) (SJ); Cc: (SANTE); (SG-RECOVER); (SJ); (SJ); (SANTE); (SANTE); (SANTE); SANTE); (SANTE); @sanita.it; (SG);); @aemps.es; @igf.finances.gouv.fr; @pm.gouv.fr; @bmg.bund.de; @bmg.bund.de @gov.se; @mz.gov.pl; @pzh.gov.pl @minvws.nl; (SANTE) Subject: Re: Typos Attachments:

As a follow-up to the below, attached please find a clean copy and redline which reflects edits to various typographical errors found by both sides. We have completed the open section of who should receive notices for AZ. The Commission's portion of this is still open for completing and, as you indicated, there is still a bracketed language for the Commission to complete at the end of the recitals.

Warm regards,

Dear Sandra and



```
From:

Date: Thursday, August 13, 2020 at 3:40 PM

To:

@ec.europa.eu

@astrazeneca.com>,

@ec.europa.eu"

Sandra Gallina

Cc:

@astrazeneca.com>,

@astrazeneca.com>,

@astrazeneca.com>,

@astrazeneca.com>,
```

```
@astrazeneca.com>,
                                              @ec.europa.eu"
                                            @ec.europa.eu"
         @ec.europa.eu>,
            @ec.europa.eu>
                                           @ec.europa.eu"
        @ec.europa.eu>,
                                            @ec.europa.eu"
                                               @ec.europa.eu"
             @ec.europa.eu>,
                                          @ec.europa.eu"
           @ec.europa.eu>,
                                     @ec.europa.eu"
       @ec.europa.eu>,
      @ec.europa.eu>
                                              @ec.europa.eu"
@ec.europa.eu>,
                                 @ec.europa.eu"
                                       @ec.europa.eu"
         @ec.europa.eu>,
                                       @ext.ec.europa.eu"
     @ec.europa.eu>,
          @ext.ec.europa.eu>,
                                      @sanita.it"
                                                         @sanita.it>,
                                                        @igf.finances.gouv.fr"
     @aemps.es"
                             @aemps.es>,
      @igf.finances.gouv.fr>,
                                                    @pm.gouv.fr"
                                      @bmg.bund.de"
           @pm.gouv.fr>,
      @bmg.bund.de>,
                                  @bmg.bund.de"
                                                              @bmg.bund.de>,
         @gov.se"
                                    @gov.se>, "
                                                      @mz.gov.pl"
                     @pzh.gov.pl"
@mz.gov.pl>, "
                                          @pzh.gov.pl>,
     @minvws.nl"
                              @minvws.nl>,
          @ec.europa.eu" <
                                                    @ec.europa.eu>
```

Subject: Re: Typos

Dear

Thank you for these. In our proof, we equally found a few small typos as well. We will combine your edits and ours into one document and send the final clean document (and redline so you can see the changes) to you shortly.

It has been a pleasure working with you and the rest of the team on this.

```
From:
                       @ec.europa.eu" <
                                                         @ec.europa.eu>
Date: Thursday, August 13, 2020 at 3:26 PM
To:
                                 @astrazeneca.com>,
                                                                   @ec.europa.eu"
Sandra Gallina
Cc:
                                      @astrazeneca.com>,
              @astrazeneca.com>,
                                                         @astrazeneca.com>,
        @astrazeneca.com>,
                                                                 @astrazeneca.com>,
                 @ec.europa.eu"
                                                 @ec.europa.eu>,
                   @ec.europa.eu"
                                                      @ec.europa.eu>,
               @ec.europa.eu"
                                              @ec.europa.eu>,
                    @ec.europa.eu" <
                                                        @ec.europa.eu>,
                  @ec.europa.eu"
                                                    @ec.europa.eu>,
```

```
@ec.europa.eu"
                                               @ec.europa.eu>,
              @ec.europa.eu"
                                             @ec.europa.eu>,
        @ec.europa.eu"
                                                  @ec.europa.eu>,
                 @ec.europa.eu"
                                                   @ec.europa.eu>,
             @ec.europa.eu"
                                            @ec.europa.eu>,
                  @ext.ec.europa.eu"
                                                        @ext.ec.europa.eu>,
         @sanita.it"
                             @sanita.it>,
                                                       @aemps.es"
             @aemps.es>,
                                         @igf.finances.gouv.fr"
              @igf.finances.gouv.fr>, "
                                                              @pm.gouv.fr" <
                                                @bmg.bund.de"
                   @pm.gouv.fr>,
              @bmg.bund.de>, '
                                            @bmg.bund.de"
                                                                         @bmg.bund.de>,
                  @gov.se"
                                                                  mz.gov.pl"
                                              @gov.se>,
       @mz.gov.pl>, '
                             @pzh.gov.pl"
                                                    @pzh.gov.pl>,
             @minvws.nl"
                                       @minvws.nl>, "
                   @ec.europa.eu"
                                                               @ec.europa.eu>,
                            @astrazeneca.com>
Subject: Typos
Dear
       , dear
In the final vetting of the document we have identified the following typos and numbering issues.
        Footnote 5 would not seem to be anymore valid, as it refers
                                                                            which is no
```

- longer in the text;
- Footnote 6 would not seem to be any more valid either, as have already been finalised;
- Paras from the order form should be deleted because the former refers erroneously to and is empty
- The paragraph in the order form should be numbered

As a cleaned text is surely in everybody's interest, we will proceed with cleaning these elements from the text in order to avoid any corrigenda procedures.

Best regards,

```
From:
                                  @astrazeneca.com>
Sent: Thursday, August 13, 2020 7:57 PM
To: GALLINA Sandra (SANTE) <
                                        @ec.europa.eu>
Сс
                                      @astrazeneca.com>;
              @astrazeneca.com>;
                                                       @astrazeneca.com>;
        @astrazeneca.com>;
                                                                 astrazeneca.com>;
                                                                            SJ)
                                          @ec.europa.eu>;
                 @ec.europa.eu>;
                                                    (COMP)
                   @ec.europa.eu>;
                                                 (SJ)
                                                                     @ec.europa.eu>;
                                           @ec.europa.eu>;
                                                                            (SANTE)
                  @ec.europa.eu>;
                                                 (SANTE)
```

```
(SANTE)
               @ec.europa.eu>;
                                                                  @ec.europa.eu>;
                                                        @ec.europa.eu>;
                                                             (SG)
                                @ec.europa.eu>;
             @ec.europa.eu>;
                 @ext.ec.europa.eu>
                                                                   @aemps.es;
                                             @sanita.it;
             @igf.finances.gouv.fr;
                                                        @pm.gouv.fr;
             @bmg.bund.de;
                                       @bmg.bund.de
                                                                       @gov.se;
      @mz.gov.pl;
                         @pzh.gov.pl;
                                                 @minvws.nl;
                                                                              (SANTE)
                          @ec.europa.eu>;
                 @astrazeneca.com>
Subject: RE: EXTREMELY URGENT ----- declaration concerning
Dear Sandra,
Please find enclosed the signed info requested.
Please let me know if you now have all info needed.
Best regards,
From: Sandra.Gallina@ec.europa.eu <Sandra.Gallina@ec.europa.eu>
Sent: 13 August 2020 18:16
To:
                                @astrazeneca.com>
Cc:
                                      @astrazeneca.com>;
              @astrazeneca.com>;
                                                       @astrazeneca.com>;
                                                               @astrazeneca.com>;
        @astrazeneca.com>;
                                                @ec.europa.eu;
                @ec.europa.eu
                  @ec.europa.eu;
                                                @ec.europa.eu;
                   @ec.europa.eu;
                                                    @ec.europa.eu;
              @ec.europa.eu;
                                          @ec.europa.eu
        @ec.europa.eu;
                                       @ec.europa.eu
                                                                  @ec.europa.eu;
                @ext.ec.europa.eu;
                                           @sanita.it;
                                                                 @aemps.es;
             @igf.finances.gouv.fr
                                                        @pm.gouv.fr;
             @bmg.bund.de;
                                       @bmg.bund.de;
                                                                       @gov.se;
      @mz.gov.pl;
                         @pzh.gov.pl;
                                                 @minvws.nl;
                  @ec.europa.eu;
                                                                    @astrazeneca.com>
Subject: RE: EXTREMELY URGENT ----- declaration concerning
```

CAUTION: This email originated outside AstraZeneca. Do not open the attachment(s) unless you recognize the sender and know the content is safe.

Now with attachments.

From: GALLINA Sandra (SANTE)

Sent: Thursday, August 13, 2020 6:14 PM

To: @astrazeneca.com>

```
Cc:
                             @astrazeneca.com>;
              @astrazeneca.com>;
                                                 @astrazeneca.com>;
                                                  @astrazeneca.com>;
        @astrazeneca.com>;
                                @ec.europa.eu>;
                                                                 (SJ)
                 @ec.europa.eu>;
                                                    (COMP)
                   @ec.europa.eu>;
                                                 (SJ)
               @ec.europa.eu>;
                                                  (SJ)
                    @ec.europa.eu>;
                                                     (SANTE)
                  @ec.europa.eu>;
                                                 (SANTE)
               @ec.europa.eu>;
                                            (SANTE)
             @ec.europa.eu>;
                                                      SANTE) <
        @ec.europa.eu>;
                                         (SANTE)
                                             (SG)
                                                               @ec.europa.eu>;
                 @ec.europa.eu>;
                                                                   @sanita.it'
                     ) <
                                        @ext.ec.europa.eu>;
         @sanita.it>;
                                @aemps.es'
                                                         @aemps.es>;
                       @igf.finances.gouv.fr)
                                                         @igf.finances.gouv.fr>;
                       @pm.gouv.fr
                                                            @pm.gouv.fr>;
             @bmg.bund.de'
                                          @bmg.bund.de>;
           @bmg.bund.de'
                                      @bmg.bund.de>;
                 @gov.se>;
                                             @mz.gov.pl)
                                                                @mz.gov.pl>;
       @pzh.gov.pl'
                                                     @minvws.nl
                            @pzh.gov.pl>;
            @minvws.nl>;
                                          (SANTE) <
                  @ec.europa.eu>;
                 @astrazeneca.com>
Subject: EXTREMELY URGENT ----- declaration concerning
Dear
I think we have a way out.
Indeed we have requested the info and it was not given.
```

As the matter is of extreme urgency, I would be very grateful to <u>receive this declaration</u> <u>today</u>.

Thank you

Date: 12 August 2020 at 14:49:38 BST To: "SANTE-PROCUREMxxx@xx.xxxopa.eu " <SANTE-PROCUREMENT@ec.europa.eu> Cc: @astrazeneca.com>, @astrazeneca.com> Subject: RE: CALL FOR TENDERS SANTE/2020/C3/037 - OFFER Dear Sante Procurement team, Thank you for your email. For clarification, please note that will share these with you as soon as we have them. Thank you From: SANTE-PROCUREMENx@xx.xxxopa.eu <SANTE-PROCUREMENT@ec.europa.eu> Sent: 10 August 2020 16:20 To: @astrazeneca.com> Cc: @astrazeneca.com>; @astrazeneca.com>; SANTE-PROCUREMENT@ec.europa.eu Subject: RE: CALL FOR TENDERS SANTE/2020/C3/037 - OFFER Dear Unless we are mistaken, we haven't received the missing evidence yet. Thank you very much for your understanding. Best regards, **SANTE Procurement Team**

@astrazeneca.com>

European CommissionDG Health and Food Safety
Unit A.3 Finance, Budget and controls

From:

Thank you very much for your understanding,

Best regards,

SANTE Procurement Team



European CommissionDG Health and Food Safety
Unit A.3 Finance, Budget and controls

From: @astrazeneca.com>

Sent: Thursday, August 13, 2020 4:15 PM

To: @astrazeneca.com>;

@astrazeneca.com>

Subject: Fwd: CALL FOR TENDERS SANTE/2020/C3/037 – OFFER

Sent from my iPhone


Begin forwarded message:


From: @astrazeneca.com> Date: 28 July 2020 at 19:12:09 BST To: "SANTE-PROCUREMENT@ec.europa.eu" <SANTE-PROCUREMENT@ec.europa.eu> Cc: @astrazeneca.com> @astrazeneca.com> Subject: RE: CALL FOR TENDERS SANTE/2020/C3/037 -OFFER Dear Sante Procurement Team,

Thank you for the confirmation below, and for the



As requested, please also find attached:







Thank you and kind regards



From: SANTE-PROCUREMENT@ec.europa.eu <SANTE-

PROCUREMENT@ec.europa.eu>

Sent: 27 July 2020 11:30

To:

@astrazeneca.com>

Cc: @astrazeneca.com>;

@astrazeneca.com>; SANTE-

PROCUREMENT@ec.europa.eu


Subject: RE: CALL FOR TENDERS SANTE/2020/C3/037 -

OFFER

CAUTION: This email originated outside AstraZeneca. Do not open the attachment(s) unless you recognize the sender and know the content is safe.

Dear ,

We confirm that the documents can be provided in parallel of the assessment of the tender and the contract discussions.



Thank you very much for your understanding,

Best regards,

SANTE Procurement Team

AstraZeneca UK Limited is a company incorporated in England and Wales with registered number:03674842 and its registered office at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.

This e-mail and its attachments are intended for the above named recipient only and may contain confidential and privileged information. If they have come to you in error, you must not copy or show them to anyone; instead, please reply to this e-mail, highlighting the error to the sender and then immediately delete the message. For information about how AstraZeneca UK Limited and its affiliates may process information, personal data and monitor communications, please see our privacy notice at www.astrazeneca.com

Confidentiality Notice: This message is private and may contain confidential and proprietary information. If you have received this message in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this message is not permitted and may be unlawful.